Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text

Life Sciences, Oncology, Pharmacotherapy +17

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

Ganesh Raghu, Martine Rémy‐Jardin, Jeffrey L. Myers et al. · American Journal of Respiratory and Critical Care Medicine · 2018 · 4.1K citations

Medicine, Clinical Sciences, Internal Medicine +17

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

Jarushka Naidoo, Xuan Wang, Kaitlin M. Woo et al. · Journal of Clinical Oncology · 2016 · 1.2K citations · Full text

Medicine, Oncology, Pathology +17